Valproic Acid and Lithium Meditate Anti-Inflammatory Effects by Differentially Modulating Dendritic Cell Differentiation and Function

Sy Jye Leu, Yi Yuan Yang, Hsing Cheng Liu, Chieh Yu Cheng, Yu Chen Wu, Ming Chyi Huang, Yuen Lun Lee, Chi Ching Chen, Winston W. Shen, Ko Jiunn Liu

研究成果: 雜誌貢獻文章

10 引文 (Scopus)

摘要

Valproic acid (VPA), with inhibition activity mainly toward histone deacetylase (HDAC) and Glycogen Synthase Kinase (GSK)-3, and lithium, with inhibition activity mainly toward GSK-3, are both prescribed in clinical as mood-stabilizers and anticonvulsants for the control of bipolar disorder. This study aims to compare the immuno-modulation activities of VPA and lithium, especially on the differentiation and functions of dendritic cells (DC). Our data show that treatment with VPA or lithium effectively alleviated the severity of collagen-induced arthritis triggered by LPS in mice. Both agents reduced the serum level of IL-6 and IL-10 after LPS challenge in mice. VPA and lithium both induce significant down-regulation of group I CD1 expression and secretion of IL-6 during differentiation of human monocyte-derived immature DC, while they differ in the induction of CD83 and CD86 expression, secretion of IL-8, IL-10, and TNF-α. Upon stimulation of immature DC with LPS, VPA, and lithium both reduced the secretion of IL-6 and TNF-α. However, only lithium significantly increased the production of IL-10, while VPA increased the production of IL-8 but substantially reduce the secretion of IL-10 and IL-23. Treatment with VPA resulted in a reduced capacity of LPS-stimulated DC to promote the differentiation of T helper 17 cells that are critical in the promotion of inflammatory responses. Taken together, our results suggest that VPA and lithium may differentially modulate inflammation through regulating the capacity of DC to mediate distinct T cell responses, and they may provide a complementary immunomodulatory effects for the treatment of inflammation-related diseases. J. Cell. Physiol. 232: 1176–1186, 2017.
原文英語
頁(從 - 到)1176-1186
頁數11
期刊Journal of Cellular Physiology
232
發行號5
DOIs
出版狀態已發佈 - 五月 1 2017

指紋

Valproic Acid
Lithium
Dendritic Cells
Cell Differentiation
Anti-Inflammatory Agents
Interleukin-10
Glycogen Synthase Kinase 3
Interleukin-6
Interleukin-8
Inflammation
Interleukin-23
Th17 Cells
Experimental Arthritis
Histone Deacetylases
T-cells
Bipolar Disorder
Anticonvulsants
Monocytes
Collagen
Down-Regulation

ASJC Scopus subject areas

  • Medicine(all)
  • Physiology
  • Clinical Biochemistry
  • Cell Biology

引用此文

Valproic Acid and Lithium Meditate Anti-Inflammatory Effects by Differentially Modulating Dendritic Cell Differentiation and Function. / Leu, Sy Jye; Yang, Yi Yuan; Liu, Hsing Cheng; Cheng, Chieh Yu; Wu, Yu Chen; Huang, Ming Chyi; Lee, Yuen Lun; Chen, Chi Ching; Shen, Winston W.; Liu, Ko Jiunn.

於: Journal of Cellular Physiology, 卷 232, 編號 5, 01.05.2017, p. 1176-1186.

研究成果: 雜誌貢獻文章

Leu, Sy Jye ; Yang, Yi Yuan ; Liu, Hsing Cheng ; Cheng, Chieh Yu ; Wu, Yu Chen ; Huang, Ming Chyi ; Lee, Yuen Lun ; Chen, Chi Ching ; Shen, Winston W. ; Liu, Ko Jiunn. / Valproic Acid and Lithium Meditate Anti-Inflammatory Effects by Differentially Modulating Dendritic Cell Differentiation and Function. 於: Journal of Cellular Physiology. 2017 ; 卷 232, 編號 5. 頁 1176-1186.
@article{59b494b8cd8f4fff951caae5eb6a95c2,
title = "Valproic Acid and Lithium Meditate Anti-Inflammatory Effects by Differentially Modulating Dendritic Cell Differentiation and Function",
abstract = "Valproic acid (VPA), with inhibition activity mainly toward histone deacetylase (HDAC) and Glycogen Synthase Kinase (GSK)-3, and lithium, with inhibition activity mainly toward GSK-3, are both prescribed in clinical as mood-stabilizers and anticonvulsants for the control of bipolar disorder. This study aims to compare the immuno-modulation activities of VPA and lithium, especially on the differentiation and functions of dendritic cells (DC). Our data show that treatment with VPA or lithium effectively alleviated the severity of collagen-induced arthritis triggered by LPS in mice. Both agents reduced the serum level of IL-6 and IL-10 after LPS challenge in mice. VPA and lithium both induce significant down-regulation of group I CD1 expression and secretion of IL-6 during differentiation of human monocyte-derived immature DC, while they differ in the induction of CD83 and CD86 expression, secretion of IL-8, IL-10, and TNF-α. Upon stimulation of immature DC with LPS, VPA, and lithium both reduced the secretion of IL-6 and TNF-α. However, only lithium significantly increased the production of IL-10, while VPA increased the production of IL-8 but substantially reduce the secretion of IL-10 and IL-23. Treatment with VPA resulted in a reduced capacity of LPS-stimulated DC to promote the differentiation of T helper 17 cells that are critical in the promotion of inflammatory responses. Taken together, our results suggest that VPA and lithium may differentially modulate inflammation through regulating the capacity of DC to mediate distinct T cell responses, and they may provide a complementary immunomodulatory effects for the treatment of inflammation-related diseases. J. Cell. Physiol. 232: 1176–1186, 2017.",
author = "Leu, {Sy Jye} and Yang, {Yi Yuan} and Liu, {Hsing Cheng} and Cheng, {Chieh Yu} and Wu, {Yu Chen} and Huang, {Ming Chyi} and Lee, {Yuen Lun} and Chen, {Chi Ching} and Shen, {Winston W.} and Liu, {Ko Jiunn}",
year = "2017",
month = "5",
day = "1",
doi = "10.1002/jcp.25604",
language = "English",
volume = "232",
pages = "1176--1186",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Valproic Acid and Lithium Meditate Anti-Inflammatory Effects by Differentially Modulating Dendritic Cell Differentiation and Function

AU - Leu, Sy Jye

AU - Yang, Yi Yuan

AU - Liu, Hsing Cheng

AU - Cheng, Chieh Yu

AU - Wu, Yu Chen

AU - Huang, Ming Chyi

AU - Lee, Yuen Lun

AU - Chen, Chi Ching

AU - Shen, Winston W.

AU - Liu, Ko Jiunn

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Valproic acid (VPA), with inhibition activity mainly toward histone deacetylase (HDAC) and Glycogen Synthase Kinase (GSK)-3, and lithium, with inhibition activity mainly toward GSK-3, are both prescribed in clinical as mood-stabilizers and anticonvulsants for the control of bipolar disorder. This study aims to compare the immuno-modulation activities of VPA and lithium, especially on the differentiation and functions of dendritic cells (DC). Our data show that treatment with VPA or lithium effectively alleviated the severity of collagen-induced arthritis triggered by LPS in mice. Both agents reduced the serum level of IL-6 and IL-10 after LPS challenge in mice. VPA and lithium both induce significant down-regulation of group I CD1 expression and secretion of IL-6 during differentiation of human monocyte-derived immature DC, while they differ in the induction of CD83 and CD86 expression, secretion of IL-8, IL-10, and TNF-α. Upon stimulation of immature DC with LPS, VPA, and lithium both reduced the secretion of IL-6 and TNF-α. However, only lithium significantly increased the production of IL-10, while VPA increased the production of IL-8 but substantially reduce the secretion of IL-10 and IL-23. Treatment with VPA resulted in a reduced capacity of LPS-stimulated DC to promote the differentiation of T helper 17 cells that are critical in the promotion of inflammatory responses. Taken together, our results suggest that VPA and lithium may differentially modulate inflammation through regulating the capacity of DC to mediate distinct T cell responses, and they may provide a complementary immunomodulatory effects for the treatment of inflammation-related diseases. J. Cell. Physiol. 232: 1176–1186, 2017.

AB - Valproic acid (VPA), with inhibition activity mainly toward histone deacetylase (HDAC) and Glycogen Synthase Kinase (GSK)-3, and lithium, with inhibition activity mainly toward GSK-3, are both prescribed in clinical as mood-stabilizers and anticonvulsants for the control of bipolar disorder. This study aims to compare the immuno-modulation activities of VPA and lithium, especially on the differentiation and functions of dendritic cells (DC). Our data show that treatment with VPA or lithium effectively alleviated the severity of collagen-induced arthritis triggered by LPS in mice. Both agents reduced the serum level of IL-6 and IL-10 after LPS challenge in mice. VPA and lithium both induce significant down-regulation of group I CD1 expression and secretion of IL-6 during differentiation of human monocyte-derived immature DC, while they differ in the induction of CD83 and CD86 expression, secretion of IL-8, IL-10, and TNF-α. Upon stimulation of immature DC with LPS, VPA, and lithium both reduced the secretion of IL-6 and TNF-α. However, only lithium significantly increased the production of IL-10, while VPA increased the production of IL-8 but substantially reduce the secretion of IL-10 and IL-23. Treatment with VPA resulted in a reduced capacity of LPS-stimulated DC to promote the differentiation of T helper 17 cells that are critical in the promotion of inflammatory responses. Taken together, our results suggest that VPA and lithium may differentially modulate inflammation through regulating the capacity of DC to mediate distinct T cell responses, and they may provide a complementary immunomodulatory effects for the treatment of inflammation-related diseases. J. Cell. Physiol. 232: 1176–1186, 2017.

UR - http://www.scopus.com/inward/record.url?scp=85000730430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000730430&partnerID=8YFLogxK

U2 - 10.1002/jcp.25604

DO - 10.1002/jcp.25604

M3 - Article

VL - 232

SP - 1176

EP - 1186

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 5

ER -